Disease · MONDO_0005347

hypertriglyceridemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypertriglyceridemia. Diseases, record MONDO_0005347. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005347

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypertriglyceridemia; Open Targets
Open Targets ID: MONDO_0005347; Open Targets
Other names: hypertriglyceridemia (disease); Open Targets
MeSH: D015228; MeSH
Highest stage of its drugs: Approval, for 5 of its 53 drugs, from DailyMed and TTD; Open Targets

Drugs53

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ICOSAPENT	CHEMBL460026	Small molecule	Approval	TTD	10	8	6	Drugs and targets
DOCONEXENT	CHEMBL367149	Small molecule	Approval	TTD	5	4	3	Drugs and targets
ICOSAPENT ETHYL	CHEMBL2095209	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
OMEGA-3-CARBOXYLIC ACIDS	CHEMBL3137327		Approval	TTD	4	3	3	Drugs and targets
VOLANESORSEN	CHEMBL3544994	Oligonucleotide	Approval	TTD	4	3	3	Drugs and targets
OMEGA-3-ACID ETHYL ESTERS	CHEMBL1200711	Small molecule	Phase 3	ClinicalTrials.gov	13	13	12	Drugs and targets
FENOFIBRATE	CHEMBL672	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
OLEZARSEN	CHEMBL4650438	Oligonucleotide	Phase 3	ClinicalTrials.gov and TTD	9	6	6	Drugs and targets
PLOZASIRAN	CHEMBL6068438	Oligonucleotide	Phase 3	ClinicalTrials.gov	7	5	4	Drugs and targets
METRELEPTIN	CHEMBL2107857	Protein	Phase 3	ClinicalTrials.gov	4	4	3	Drugs and targets

1 to 10 of 53

See all 53 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PPARA	Peroxisome proliferator-activated receptor	7	Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist	Phase 3	https://conductscience.org/library/genes/5465	Drugs and targets
APOC3	Apolipoprotein C-III mRNA	3	Apolipoprotein C-III mRNA 3'UTR antisense inhibitor; Apolipoprotein C-III mRNA antisense inhibitor	Approval	https://conductscience.org/library/genes/345	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	3	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor	3	Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist	Phase 2	https://conductscience.org/library/genes/5468	Drugs and targets
ANGPTL3	Angiopoietin like 3 (ANGPTL3) mRNA	2	Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor; Angiopoietin-related protein 3 inhibitor	Phase 2	https://conductscience.org/library/genes/27329	Drugs and targets
LEPR	Leptin receptor	2	Leptin receptor agonist	Phase 3	https://conductscience.org/library/genes/3953	Drugs and targets
MTTP	Microsomal triglyceride transfer protein	2	Microsomal triglyceride transfer protein inhibitor	Phase 2	https://conductscience.org/library/genes/4547	Drugs and targets
P4HB	Microsomal triglyceride transfer protein	2	Microsomal triglyceride transfer protein inhibitor	Phase 2	https://conductscience.org/library/genes/5034	Drugs and targets
ADORA1	Adenosine receptor A1	1	Adenosine A1 receptor partial agonist	Phase 1	https://conductscience.org/library/genes/134	Drugs and targets
ASGR1	Asialoglycoprotein receptor 1	1	Asialoglycoprotein receptor 1 binding agent	Phase 2	https://conductscience.org/library/genes/432	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials91

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03415152	A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy		3,000	2020-10-12	History of Myocardial Infarction, Hypertriglyceridemia	OMEGA-3-ACID ETHYL ESTERS	Its record names the disease	ClinicalTrials.gov
NCT01408303	[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL	Phase 3	646	2014-12-05	Hypertriglyceridemia, Cardiovascular Disease	OMEGA-3-CARBOXYLIC ACIDS	Its record names the disease	ClinicalTrials.gov
NCT01350973	Efficacy of TAK-085 in Participants With Hypertriglyceridemia	Phase 3	611	2016-09-20	Hypertriglyceridemia	ICOSAPENT, OMEGA-3-ACID ETHYL ESTERS	Its record names the disease	ClinicalTrials.gov
NCT01350999	Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia	Phase 3	503	2016-09-20	Hypertriglyceridemia	ICOSAPENT, OMEGA-3-ACID ETHYL ESTERS	Its record names the disease	ClinicalTrials.gov
NCT00812955	Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides	Phase 3	474	2012-08-01	Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia	FENOFIBRIC ACID, ROSUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT03011450	Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment	Phase 3	471	2022-10-28	Severe Hypertriglyceridemia	K-877	Its record names the disease	ClinicalTrials.gov
NCT01242527	Epanova® for Lowering Very High Triglycerides	Phase 2/3	399	2013-09-06	Severe Hypertriglyceridemia	OMEGA-3-CARBOXYLIC ACIDS	Its record names the disease	ClinicalTrials.gov
NCT02009865	Epanova® for Lowering Very High Triglycerides II (EVOLVE II)	Phase 3	379	2016-01-15	Hypertriglyceridemia	OMEGA-3-CARBOXYLIC ACIDS	Its record names the disease	ClinicalTrials.gov
NCT00435045	Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia	Phase 3	245	2009-05-12	Hypertriglyceridemia	ATORVASTATIN, OMEGA-3-ACID ETHYL ESTERS	Its record names the disease	ClinicalTrials.gov
NCT04365400	Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes	Phase 2	233	2023-06-01	Hypertriglyceridemia, Type 2 Diabetes	EPELEUTON	Its record names the disease	ClinicalTrials.gov

1 to 10 of 91

See all 91 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Omega-3 Pentaenoic Acid (MAT9001) vs Icosapent Ethyl (Vascepa): deaths from any cause	0 of 97	0 of 100	197	NCT04177680	Trial comparisons
Omega-3 Pentaenoic Acid (MAT9001) vs Icosapent Ethyl (Vascepa): serious adverse events	0 of 97	0 of 100	197	NCT04177680	Trial comparisons
Epanova vs Olive Oil: serious adverse events	1 of 81	2 of 81	162	NCT02009865	Trial comparisons
Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3	65 of 75	5 of 38	113	NCT02300233	Trial comparisons
Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG < 150 mg/dL Reduction From Baseline at Month 3	11 of 75	0 of 38	113	NCT02300233	Trial comparisons
Pegozafermin vs Placebo: Number of Participants Who Achieved TG <500 mg/dL at Week 8	51 of 64	5 of 17	81	NCT04541186	Trial comparisons
Intervention vs Control: serious adverse events	0 of 25	0 of 29	54	NCT01280604	Trial comparisons
POM3 vs Placebo: serious adverse events	0 of 23	0 of 23	46	NCT01034540	Trial comparisons
Lovaza vs Placebo: serious adverse events	0 of 12	0 of 12	24	NCT00672633	Trial comparisons
Arm 2 Combined Cohort A + B: REGN4461 to REGN4461 vs Arm 1 Combined Cohort A + B: Placebo to REGN4461: Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response	0 of 10	0 of 10	20	NCT05088460	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials67

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39924184	RESULT	1	PubMed
39098034	RESULT	1	PubMed
38616112	RESULT	1	PubMed
37355760	RESULT	1	PubMed
35492338	RESULT	1	PubMed
27939227	RESULT	1	PubMed
27596132	RESULT	1	PubMed
27418543	RESULT	1	PubMed
27206952	RESULT	1	PubMed
25893544	RESULT	1	PubMed

1 to 10 of 67

See all 67 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005347

GET https://conductscience.org/api/diseases/v1/MONDO_0005347/drugs?page=2

API reference For AI assistants